Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib with DA-EPOCH-R in Aggressive B-cell Lymphomas
NCT04933617Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of copanlisib in Burkitt lymphoma (BL), high grade B-cell lymphoma (HGBCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (2 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days and Recommended Phase II Dose at 21 days. Started Mar 2022; status: terminated.
02
Drugs
copanlisib
03
Conditions
Burkitt lymphoma (BL)high grade B-cell lymphoma (HGBCL)diffuse large B-cell lymphoma (DLBCL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on NCT04933617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933617.